Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-06-14
2011-06-14
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C530S388300
Reexamination Certificate
active
07959922
ABSTRACT:
The present invention provides pharmaceutical antibody formulations, in particular liquid pharmaceutical formulations comprising anti-rabies virus antibodies. The formulations can be used in the post exposure prophylaxis of rabies.
REFERENCES:
patent: 7579446 (2009-08-01), Bakker et al.
patent: 7740852 (2010-06-01), Bakker et al.
patent: 2004/0013672 (2004-01-01), Hooper et al.
patent: 2006/0263802 (2006-11-01), Bakker et al.
patent: 2008/0070799 (2008-03-01), Bakker et al.
patent: 2010/0272724 (2010-10-01), Bakker et al.
patent: 2010/0310572 (2010-12-01), Bakker et al.
patent: 7198291 (1991-09-01), None
patent: 0 402 029 (1990-12-01), None
patent: 0 445 625 (1991-09-01), None
patent: WO 98/15833 (1998-04-01), None
patent: WO 03/016501 (2003-02-01), None
patent: WO 2004/009618 (2004-01-01), None
patent: WO 2005/023849 (2005-03-01), None
patent: WO 2005/118644 (2005-12-01), None
patent: WO 2006/112838 (2006-10-01), None
patent: WO 2008/068246 (2008-06-01), None
Prosniak et al (Journal of Infectious Diseases 188:53-56, 2003).
Champion et al (Journal of Immunological Methods 235:81-90, 2000).
Wang et al (Journal of Pharmaceutical Sciences 96:1-26, 2007).
PCT International Search Report, PCT/EP2007/063244, dated Apr. 2, 2008.
PCT Written Opinion, PCT/EP2007/063244 dated Apr. 2, 2008.
Notice of Allowance for U.S. Appl. No. 10/517,941 dated Apr. 8, 2009.
Office Action for U.S. Appl. No. 11/317,786 dated Mar. 17, 2009.
Notice of Allowance for U.S. Appl. No. 11/590,126 dated Apr. 10, 2009.
Office Action for U.S. Appl. No. 11/978,742 dated Mar. 25, 2009.
Kramer et al., Abstract, Immunity to infection: The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries, Eur. J. Immunol., 35: 2131-2145 (2005).
Schumacher et al. “Use of mouse anti-rabies monoclonal antibodies in post-exposure treatment of rabies.” J. Clin. Invest. 84:971-975 (1989).
Paul, Fundamental Immunology, (textbook), 1993, pp. 292-95, Lippincott-Raven Publishers, Philadelphia, PA.
Database Genbank NCBI; Jun. 26, 2003, Prosniak, M. et al., “Homo sapieansanti-rabies S057 immunoglobul in heavy chain mRNA” XP 002356864, retrieved from http://www.ncbi.nlr.nih.gov, Database accession No. AY172957.
Database Genbank NCBI; Jun. 26, 2003, Prosniak, M. et al., “Homo sapieansanti-rabies S057 immunoglobul in lambda light chain mRNA” XP 002356865, retrieved from http://www.ncbi.nlr.nih.gov, Database accession No. AY172960.
PCT International Search Report, PCT/EP2005/052410, dated Jan. 1, 2006.
PCT International Preliminary Report on Patentability, PCT/EP2005/052410, dated Aug. 28, 2006.
Prosniak et al., “Development of a Cocktail of Recombinant-Expressed Human Rabies Virus-Neutralizing Monoclonal Antibodies for Postexposure Prophylaxis of Rabies,” Journal of Infectious Diseases, Jul. 1, 2003, pp. 53-56, vol. 188.
Champion et al., “The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure,” Journal of Immunological Methods, 2000, pp. 81-90, vol. 235.
Dietzschold et al., “Biological Characterization of Human Monoclonal Antibodies to Rabies Virus,” Journal of Virology, Jun. 1990, pp. 3087-3090, vol. 64, No. 6.
Hanlon et al., “Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis,” Vaccine, 2001, pp. 3834-3842, vol. 19.
Jones et al., “High-level Expression of Recombinant IgG in the Human Cell Line Per.C6,” Biotechnol. Prog., 2003, pp. 163-168, vol. 19.
De Kruif et al., “Selection and Application of Human Single Chain Fv Antibody Fragments from a Semi-synthetic Phage Antibody Display Library with Designed CDR3 Regions.” J. Mol. Biol., 1995, pp. 97-105, vol. 248.
U.S. Appl. No. 10/517,941, filed Dec. 13, 2004, Inventor: Bakker et al, Title: Antibody to the Human OX40 Receptor.
U.S. Appl. No. 11/317,786, filed Dec. 22, 2005, Inventor: van den Oudenrijn et al., Title: Binding Molecules for the Treatment of Myeloid Cell Malignancies.
U.S. Appl. No. 11/590,126, filed Oct. 31, 2006, Inventor: Bakker et al., Title: Binding Molecules Capable of Neutralizing Rabies Virus and Uses Thereof.
U.S. Appl. No. 11/978,742, filed Oct. 29, 2007, Inventor: Bakker et al., Title: Binding Molecules Capable of Neutralizing Rabies Virus and Uses Thereof.
U.S. Appl. No. 11/980,237, filed Oct. 29, 2007, Inventor: Bakker et al., Title: Binding Molecules Capable of Neutralizing Rabies Virus and Uses Thereof.
U.S. Appl. No. 12/383,330, filed Mar. 23, 2009, Inventor: Bakker et al., Title: Agonistic Binding Molecules to the Human OX40 Receptor.
Daugherty et al., Formulation and delivery issues for monoclonal antibody therapeutics, Advanced Drug Delivery Reviews, 2006, pp. 686-706, vol. 58, Science Direct.
PCT International Preliminary Report on Patenability, PCT/EP2004/052043, dated Dec. 21, 2005.
PCT International Search Report, PCT/EP2004/052043, dated Apr. 21, 2005.
Database Geneseq ′Online! Dec. 18, 2003, “Wild-type rabies virus G protein.” XP002323001, retrieved from EBI accession No. GSN:ACD37470, Database accession No. ADC37470.
Database USPTO Proteins ″Online! May 14, 2004. “Sequence 59 from patent US 6,706,523.” XP002323002, retrieved from EBI accession No. USPOP:AAT21621, Database accession No. AAT21621.
Database Geneseq ′Online! Dec. 18, 2003, “Mutant rabies virus G protein,” XP002323003, retrieved from EBI accession No. GSN:ADC3747I, Database accession No. ADC37471.
Database USPTO Proteins ″Online! May 14, 2004, “Sequence 60 from patent US 6,706,523.” XP002323004, retrieved from EBI accession No. USPOP:AAT21622, Database accession No. AAT21622.
Fodor et al., “Nucleotide and deduced amino acid sequences of the glycoprotein gene of rabies virus vaccine strain Vnukovo-32,” Archives of Virology, 1994, pp. 451-459, vol. 135, No. 3-4.
Database NCBI ′ Online! Jun. 1, 2001, Jayakumar: XP0002323005, retrieved from EBI accession No. Q99AU1. Database accession No. Q99AU1.
Database JPO Proteins ′Online! Apr. 27, 1998, “A recombinant Glycoprotein,” XP002323006, retrieved from EBI accession No. JPOP:E61000, Database accession No. E61000.
Database Geneseq ′Online! Mar. 21, 1997, “Recombinant abies virus G protein,” XP002323007, retrieved from EBI accession No. GSN:AAW09380, Database accession No. AAW09380.
Dietzschold et al., “Chemical and Immunological Analysis of the rabies Soluble Glycoprotein,” Virology, 1983, pp. 330-337, vol. 124, No. 2.
Benmansour et al., Antigenicity of Rabies Virus Glycoprotein, Journal of Virology, 1991, pp. 4198-4203, vol. 65, No. 8.
De Haard et al., A Large Non-immunized Human Fab Fragment Phage Library That Permits Rapid Isolation and Kinetic Analysis of High Affinity Antibodies. 1999, Journal of Biological Chemistry, pp. 18218-18230, vol. 274, No. 26.
De Kruif et al., Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library, 1995, Proceedings of the National Academy of Sciences of the United States of America. vol. 92, pp. 3938-3942.
Dietzschold et al., “New Approaches to the Development of Live Attenuated Rabies Vaccines,” Hybridoma and Hybridomics, Apr. 2002, pp. 129-134, vol. 21, No. 2.
Dietzschold et al., “Structural and Immunological Characterization of a Linear Virus-Neutralizing Epitope of the Rabies Virus glycoprotein and its Possible Use in a Synthetic Vaccine,” Journal of Virology, Aug. 1990, pp. 3804-3809, vol. 64, No. 8.
Drings et al., “Is there an advantage to including the nucleoprotein in a rabies glycoprotein subunit vaccine?” Vaccine, 1999, pp. 1549-1557, vol. 17, No. 11/12.
Fu et al., “Oral vaccination of raccoons (Procyon lotor) with baculovirus-expressed rabies virus glycoprotein,” Vaccine, 1993, pp. 925-928, vol. 11, No
Bakker Alexander B. H.
Marissen Willem E.
Crucell Holland B.V.
Mosher Mary E
TraskBritt P.C.
LandOfFree
Liquid anti-rabies antibody formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Liquid anti-rabies antibody formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liquid anti-rabies antibody formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2678940